吉非替尼一线治疗肺结核合并非小细胞肺癌的临床观察(3)
[6] LorussoPM，Herbst RS，Rischn D，et al.Improvements in quality of 1ife and disease-related symptoms in phase trials of the selective oral Epidermal growth factor receptor tyrosine kinase inhibitor ZD l839 in nonsmall cell lung cancer and other solid tumors.C1in Cancer Res,2003,9:2040-2048.
[7] Ranson M，Hammond LA，Perry D，et al.ZD 1839，a selective oral Epidermal growth factor receptor tyrosine Kinase inhibnor is well Tolerated and active inpatients with so1id，m alignant tumors：results ofa Phase I trial.Clin Oncol,2002,20:2240-2250.
[8] Paez JG,Janne PA,Lee JC,et al.ECFR mutation in lung cancer：Correlation with clinical response togefldnib therapy.Scinece,2004,304:1497-1500.
[9] Bianco R，Shn I，Ritter CA，et al.Loss of PTEN/MMACl/TEP in EGF Receptor expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.Oncogene，2003，22(18)：2812-2822.
[10] Mohamed MK，Ramalingam S，LinY，et al.Skin rash and good performance status predict improved Survival with gefitinibinpatients with adwanced non-small cell lung cancer.Ann Oncol,2005,16(5):780-785.
[11] Spigel DR,Hainsworth JD,Burkett ER,et al.Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status:a Minnie Pearl Cancer Research Network Phase Ⅱ Trial.Clin Lung Cancer,2005,7(2):127-132., 百拇医药(姜宏宁 史 菎 余 敏)
[7] Ranson M，Hammond LA，Perry D，et al.ZD 1839，a selective oral Epidermal growth factor receptor tyrosine Kinase inhibnor is well Tolerated and active inpatients with so1id，m alignant tumors：results ofa Phase I trial.Clin Oncol,2002,20:2240-2250.
[8] Paez JG,Janne PA,Lee JC,et al.ECFR mutation in lung cancer：Correlation with clinical response togefldnib therapy.Scinece,2004,304:1497-1500.
[9] Bianco R，Shn I，Ritter CA，et al.Loss of PTEN/MMACl/TEP in EGF Receptor expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.Oncogene，2003，22(18)：2812-2822.
[10] Mohamed MK，Ramalingam S，LinY，et al.Skin rash and good performance status predict improved Survival with gefitinibinpatients with adwanced non-small cell lung cancer.Ann Oncol,2005,16(5):780-785.
[11] Spigel DR,Hainsworth JD,Burkett ER,et al.Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status:a Minnie Pearl Cancer Research Network Phase Ⅱ Trial.Clin Lung Cancer,2005,7(2):127-132., 百拇医药(姜宏宁 史 菎 余 敏)